Mirabegron

CAS 223673-61-8 39 current recordsSmall Molecule

Who holds supplier records for Mirabegron? 39 organisations hold a current record for Mirabegron: an active US FDA Type II Drug Master File or a CEP. 20 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (28), China (6), Italy (1), Spain (1) and 2 other countries (2); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Mirabegron: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/mirabegron

Reading the evidence

  • 39 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    28 of the 38 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 20 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Mirabegron expires 30 Sept 2036. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (39)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Mirabegron. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Mirabegron sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (20)

Certificates of Suitability on the EDQM register for Mirabegron, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 22 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
NEULAND LABORATORIES LIMITED HyderabadIN
CEP 2023-314 - Rev 01
Mirabegron
Nov 2026—
ZYDUS LIFESCIENCES LIMITED VadodaraIN
CEP 2024-378 - Rev 01
Mirabegron
Sept 2026—
ALIVUS LIFE SCIENCES LIMITED MumbaiIN
CEP 2024-056 - Rev 01
Mirabegron
May 2026—
SYNTHIMED LABS PRIVATE LIMITED DerabassiIN
CEP 2025-017 - Rev 00
Mirabegron
May 2026Inspected Aug 2026
Slovenia
VIWIT PHARMACEUTICAL CO. LTD TengzhouCN
CEP 2024-039 - Rev 00
Mirabegron
Jan 2026—
MEGAFINE PHARMA PRIVATE LIMITED MumbaiIN
CEP 2024-087 - Rev 02
Mirabegron
Nov 2025—
SOLARA ACTIVE PHARMA SCIENCES LIMITED ChennaiIN
CEP 2024-015 - Rev 00
Mirabegron
Nov 2025—
PIRAMAL PHARMA LIMITED Digwal VillageIN
CEP 2024-093 - Rev 00
Mirabegron, Alpha form
Sept 2025Inspected Jun 2025
Netherlands
BIOCON LIMITED BengaluruIN
CEP 2023-460 - Rev 00
Mirabegron
Aug 2025—
LEWENS LABS PRIVATE LIMITED DahejIN
CEP 2024-344 - Rev 00
Mirabegron
Jul 2025—
VASUDHA PHARMA CHEM LIMITED HyderabadIN
CEP 2024-198 - Rev 00
Mirabegron
Jul 2025—
MSN LABORATORIES PRIVATE LIMITED Rudraram VillageIN
CEP 2024-031 - Rev 00
Mirabegron, α-Form
Jul 2025—
DR. REDDY'S LABORATORIES LIMITED HyderabadIN
CEP 2024-033 - Rev 00
Mirabegron, Form-α
Jun 2025—
AMOLI ORGANICS PRIVATE LIMITED MumbaiIN
CEP 2024-208 - Rev 00
Mirabegron, alpha form
Jun 2025—
SHANDONG LONCOM PHARMACEUTICAL CO., LTD DezhouCN
CEP 2023-286 - Rev 00
Mirabegron
Jun 2025—
ZHEJIANG HUAYI PHARMACEUTICAL CO., LTD. JinhuaCN
CEP 2024-037 - Rev 00
Mirabegron
May 2025—
AMI LIFESCIENCES PRIVATE LIMITED VadodaraIN
CEP 2024-105 - Rev 00
Mirabegron
May 2025Inspected Oct 2025
Slovakia
MICRO LABS LIMITED BengaluruIN
CEP 2023-308 - Rev 00
Mirabegron
Apr 2025—
ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. TaizhouCN
CEP 2023-249 - Rev 00
Mirabegron, Micronised and non-micronised
Apr 2025Inspected May 2026
Italy
JIANGXI SYNERGY PHARMACEUTICAL CO., LTD. YichunCN
CEP 2023-180 - Rev 02
Mirabegron
Oct 2024—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (18 listed products contain Mirabegron). The latest listed patent expires 30 Sept 2036. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Mirabegron is a beta-3 adrenergic agonist used for the treatment of overactive bladder. It works by relaxing the detrusor muscle in the bladder, increasing its storage capacity.

Chemical identity

IUPAC name
2-(2-amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide
Canonical SMILES
C1=CC=C(C=C1)[C@H](CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O
InChIKey
PBAPPPCECJKMCM-IBGZPJMESA-N
Synonyms
Myrbetriq API, betanis, betmiga, myrbetriq, ym-178, ym178

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
beta3-Adrenergic Agonist
Mechanism of action
Adrenergic beta3-Agonists; Cytochrome P450 2D6 Inhibitors; Cytochrome P450 3A Inhibitors; P-Glycoprotein Inhibitors

Therapeutic areas

UrologyOveractive Bladder

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Mirabegron?

39 organisations hold an active US FDA Type II Drug Master File or a CEP for Mirabegron: Dr. Reddy's Laboratories Ltd. (India), MSN Laboratories Private Limited (India), ALIVUS LIFE SCIENCES LTD (India), AMI LIFESCIENCES PRIVATE LTD (India), AMOLI ORGANICS PRIVATE LTD (India), Biocon Limited (India), Jiangxi Synergy Pharmaceutical Co., Ltd (China) and MICRO LABS LTD (India), and 31 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Mirabegron Drug Master Files are active?

Dr. Reddy's Laboratories Ltd. (DMF 30413, 28392), MSN Laboratories Private Limited (DMF 36682, 28071), ALIVUS LIFE SCIENCES LTD (DMF 30065), AMI LIFESCIENCES PRIVATE LTD (DMF 40421), AMOLI ORGANICS PRIVATE LTD (DMF 38825), Biocon Limited (DMF 35117), Jiangxi Synergy Pharmaceutical Co., Ltd (DMF 31661) and MICRO LABS LTD (DMF 29734) and 27 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

Does Mirabegron have a European Certificate of Suitability?

Yes. 20 organisations hold a valid CEP for Mirabegron on the EDQM register, including NEULAND LABORATORIES LIMITED Hyderabad (IN), ZYDUS LIFESCIENCES LIMITED Vadodara (IN), ALIVUS LIFE SCIENCES LIMITED Mumbai (IN), SYNTHIMED LABS PRIVATE LIMITED Derabassi (IN), VIWIT PHARMACEUTICAL CO. LTD Tengzhou (CN) and MEGAFINE PHARMA PRIVATE LIMITED Mumbai (IN) and 14 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Mirabegron?

Yes. The latest patent listed for an approved US product containing Mirabegron expires 30 Sept 2036, across 18 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Mirabegron supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Mirabegron?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.